Panacea Biotec has secured substantial additional vaccine orders from UNICEF, strengthening its position as a key supplier of WHO pre-qualified vaccines. The pharmaceutical company received updates to its existing UNICEF contract for supplying the pentavalent vaccine Easyfive-TT (DTwP-HepB-Hib) for the 2023-2027 period, as well as new awards for pentavalent and polio vaccines.

Contract Value Increases and New Awards

The UNICEF contract updates demonstrate significant growth in order volumes across multiple years:

The combined additional orders total approximately $8.93 million, representing around ₹80.00 crores in new business for the company.

Polio Vaccine Supply Agreement

Beyond the pentavalent vaccine contract updates, Panacea Biotec also secured a significant polio vaccine order from UNICEF in October. The company received a letter of award as part of a long-term agreement to supply bivalent oral polio vaccine (bOPV) in both 10 and 20-vial presentations.

Market Performance

The positive developments were reflected in the company's stock performance, with shares closing at ₹359.50 on December 24, registering a gain of 0.93% on the day. This uptick suggests investor confidence in the company's expanding vaccine supply partnerships with international organizations.

Strategic Significance

These UNICEF contracts underscore Panacea Biotec's capabilities in manufacturing WHO pre-qualified vaccines and its role in global immunization programs. The pentavalent vaccine Easyfive-TT combines protection against diphtheria, tetanus, whooping cough, hepatitis B, and Haemophilus influenzae type b, making it a crucial component of childhood immunization schedules worldwide.

The additional orders, including contract value increases for 2026-2027 and new awards for pentavalent and polio vaccines, further solidify Panacea Biotec's position as a key player in the global vaccine market and its commitment to supporting UNICEF's immunization efforts.

Panacea Biotec has announced a significant enhancement to its vaccine supply contract with UNICEF, marking a major development for the pharmaceutical company's international operations. The contract amendment includes both value increases to existing awards and an additional new award for vaccine supply.

Contract Amendment Details

UNICEF has amended its contract with Panacea Biotec for the supply of WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib). The amendment encompasses three key components across the 2026-2027 period.

Award Value Adjustments

The contract modifications include substantial increases to existing award values. For 2026, the contract value increases from $14.25 million to $16.80 million. In 2027, the value rises from $12.48 million to $15.18 million, alongside the additional $3.68 million award for Easyfive-TT supply.

Regulatory Disclosure

Panacea Biotec disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure follows the company's earlier communication from October 10, 2022, regarding the initial UNICEF Letter of Award for supplies during calendar years 2023-2027.

Strategic Impact

This contract amendment reinforces UNICEF's confidence in Panacea Biotec's vaccine manufacturing capabilities and supply chain reliability. The total enhancement of $8.93 million (₹80 crore) represents a significant addition to the company's international vaccine supply revenue stream, providing enhanced visibility for the pharmaceutical company's operations through 2027.